GlobeNewswire by notified

Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

Share
  • CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2
  • Graft-versus-host disease (GvHD) is a serious and debilitating complication of stem cell transplants, with no established standard of care for patients who do not adequately respond to first-line steroid treatment3,4
  • Nearly half of patients experience either acute or chronic GvHD, or both, following allogeneic transplants3,4

Basel, March 25, 2022 — Novartis announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jakavi® (ruxolitinib) for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease (GvHD) who have inadequate response to corticosteroids or other systemic therapies. If approved, Jakavi will be the first JAK1/2 inhibitor available for patients with GvHD in Europe4.

“For many hematologic diseases, allogeneic transplant is the only treatment with the potential to be curative; however, half will go on to develop acute or chronic GvHD,” said Dr. Robert Zeiser, University Hospital Freiburg, Department of Haematology, Oncology and Stem Cell Transplantation, Freiburg, Germany. “It is encouraging that we may soon have a new standard of care for patients with this often debilitating condition who do not adequately respond to first-line corticosteroids or other systemic therapies.”

The CHMP positive opinion was based on data from the Phase III REACH2 and REACH3 clinical studies, in which Jakavi demonstrated superiority versus best available therapy (BAT) in patients with steroid-refractory and steroid-dependent acute and chronic GvHD, respectively.

Results from the REACH2 trial showed that overall response rate (ORR) at Day 28 was superior in the Jakavi arm at 62.3% vs. 39.4% in the BAT arm (odds ratio [OR], 2.64; p<0.001) in patients with steroid refractory/dependent acute GvHD. In those patients who maintained response at Day 56, the ORR in the Jakavi arm was 40% vs. 22% in the BAT arm (p<0.001). In REACH3, treatment with Jakavi led to significant improvements in ORR compared to BAT (49.7% vs. 25.6%; OR, 2.99; P<0.0001) in patients with steroid-refractory/dependent chronic GvHD at week 24, the primary endpoint of the study, regardless of the individual organs involved at baseline. Also, best overall response (BOR) rate at any time up to week 24 was achieved in 76.4% of patients in the Jakavi arm compared to 60.4% in the BAT arm (OR, 2.17; 95% CI, 1.34-3.52). Results from the two studies were published in the April 22, 2020 (REACH2), and July 15, 2021 (REACH3) issues of The New England Journal of Medicine1,2.

GvHD, a common and potentially life-threatening complication that can arise after allogeneic stem cell transplants, is a reaction where the donor’s cells see the recipient’s normal cells as foreign and attack them. Symptoms of GvHD can appear in the skin, gastrointestinal tract, liver, mouth, eyes, genitals, lungs, and joints3,5-8.

Approximately 50 percent of allogeneic stem cell transplant recipients experience either acute or chronic GvHD, or both4. Acute GvHD typically occurs within the first 100 days of transplant, while chronic GvHD generally occurs more than 100 days after transplant. Both acute and chronic GvHD can be fatal and until now both have lacked an established standard of care for patients who do not adequately respond to first-line steroid treatment3,4.

“This positive CHMP opinion for Jakavi in GvHD brings us one step closer to approval in Europe, for a condition where patients often experience severe and life-threatening symptoms,” said Susanne Schaffert, PhD, President, Novartis Oncology. “With this exciting news, we may change the way GvHD is treated as about half of patients do not respond to previous corticosteroids or other systemic treatment.”

The CHMP’s positive opinion of Jakavi in acute and chronic GvHD will be referred to the European Commission (EC), which has the authority to grant marketing authorizations for medications in the EU. The EC will review the CHMP recommendations and is expected to make a final decision within approximately 2 months.

About Jakavi® (ruxolitinib)
Jakavi® (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. Jakavi is approved by the European Commission for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea and for the treatment of disease- related splenomegaly or symptoms in adult patients with primary myelofibrosis (MF) (also known as chronic idiopathic MF), post-polycythemia vera MF or post-essential thrombocythemia MF. Jakavi is approved in over 100 countries for patients with MF, including EU countries, Switzerland, Canada, Japan and in more than 85 countries for patients with PV, including EU countries, Switzerland, Japan and Canada. The exact indication for Jakavi varies by country. Additional worldwide regulatory filings are underway in MF and PV.

Novartis licensed ruxolitinib from Incyte for development and commercialization outside the United States. Ruxolitinib is marketed in the United States by Incyte as Jakafi® for adults with PV who have had an inadequate response to or are intolerant of hydroxyurea, for adults with intermediate or high-risk MF, for adult and pediatric patients 12 years and older with steroid-refractory acute GvHD, and adult and pediatric patients 12 years and older with chronic GvHD after failure of one or two lines of corticosteroids or other systemic therapy.

Jakavi is a registered trademark of Novartis AG in countries outside the United States. Jakafi is a registered trademark of Incyte. The safety and efficacy profile of Jakavi has not yet been established outside of its approved indications.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit http://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

  1. Zeiser R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease (REACH3). New England Journal of Medicine; July 2021.
  2. Zeiser, R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease (REACH2). New England Journal of Medicine. April 2020.
  3. Leukemia and Lymphoma Society. Graft-Versus-Host Disease Overview. 2021. Available at: https://www.lls.org/treatment/types-treatment/stem-cell-transplantation/graft-versus-host-disease
  4. Jaglowski SM, et al. Graft-versus-Host Disease: Why Haven’t We Made More Progress? Curr Opin Hematol. 2014;21(2):141-147 
  5. Ferrara JL., et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561. 
  6. Zeiser R., et al. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017 Dec 28;377(26):2565-2579
  7. Jagasia MH, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015.
  8. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Amy Wolf
Novartis External Communications
+41 79 576 0723 (mobile)
Amy.Wolf@novartis.com

Michael Billings
Novartis Hematology Communications
+1 862 788 8656 (direct)
+1 201 400 1854 (mobile)
Michael.Billings@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 345 4440
Nicole Zinsli-Somm+4 16 132 43809Alina Levchuk+1 862 778 3372
Isabella Zinck+41 61 324 7188Parag Mahanti+1 973-876-4912
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GOGL - Mandatory notification of trade by primary insiders19.5.2022 22:30:00 CEST | Press release

Eligible option holders in Golden Ocean Group Ltd (the “Company”) have today exercised share options in accordance with the terms previously announced. Ulrik Uhrenfeldt Andersen, CEO, has exercised 300,000 share options and subsequently sold 300,000 shares. Following the exercise, Mr. Andersen holds 250,000 share options. Peder Simonsen, CFO, has exercised 75,000 share options and has subsequently sold 75,000 shares. Following the exercise, Mr. Simonsen holds 200,000 share options and 500 shares. Please see the attached forms for notification and public disclosure of transaction attached for details. This notification has been publicly disclosed in accordance with Article 19 of the Market Abuse Regulation section 5-12 of the Norwegian Securities Trading Act. Attachment GOGL - Disclosure of transaction by PDMR

Brunel AGM 202219.5.2022 18:30:00 CEST | Press release

Amsterdam, 19 May 2022 – Brunel International N.V. (Brunel; BRNL), a global provider of flexible workforce solutions and expertise, today announced the voting results of the Annual General Meeting of Shareholders (AGM) of 19 May 2022. The AGM approved all voting items that were on the agenda. The shareholders adopted the financial statements for the 2021 financial year and approved the proposal to distribute a dividend of € 0.45 per share for the 2021 financial year. The dividend, less 15% dividend withholding tax, will be made payable as of 15 June 2022 at ABN AMRO Bank N.V. in Amsterdam. The shares will be quoted ex-dividend on the stock exchange of Euronext Amsterdam as of 23 May 2022. The record date is 24 May 2022 after closing of the stock exchange. Peter de Laat is reappointed as a member of the board of directors for a new term of four years. At the close of the meeting Mr Jan Arie van Barneveld, retired from the supervisory board after having served on the supervisory board fo

Scandinavian Tobacco Group A/S: Share buy-back programme increased to up to DKK 1,000 million19.5.2022 18:15:00 CEST | Press release

Company Announcement No. 35/2022 Copenhagen, 19 May 2022 Share buy-back programme increased to up to DKK 1,000 million The Board of Directors of Scandinavian Tobacco Group A/S has decided to increase the DKK 700 million share buy-back programme that was initiated 10 March 2022 (see company announcement 16/2022) by DKK 300 million. Consequently, the on-going share buy-back programme now has a value of up to DKK 1,000 million. As of 19 May 2022, Scandinavian Tobacco Group had purchased shares of a total value of DKK 128 million under the programme. Prior to the expansion of the share buy-back programme, Scandinavian Tobacco Group A/S holds a total of 1,338,431 treasury shares, corresponding to 1.44% of the total share capital. The purpose of the share buy-back programme remains to adjust the Group’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The Board of Directors intends to propose to the annual general meeting in 2023 that the shares

Scandinavian Tobacco Group A/S reports Q1 results, maintains guidance for 2022 and presents revised Sustainability Strategy19.5.2022 18:15:00 CEST | Press release

Company Announcement No. 34/2022 Copenhagen, 19 May 2022 Interim report, 1 January - 31 March 2022 Scandinavian Tobacco Group A/S reports Q1 results, maintains guidance for 2022 and presents revised Sustainability Strategy For the first quarter of 2022 Scandinavian Tobacco Group delivered 2% negative organic net sales growth and 3% negative organic EBITDA growth in line with the previously communicated expectations for the quarter. The guidance for the full year of an organic EBITDA growth in the range of 0-6% is maintained. The uncertainty related to key assumptions like consumer behaviour, cost inflation and supply-chain stability remains high. The current share buy-back programme is increased by DKK 300 million to reach up to DKK 1,000 million reflecting the strong financial position of Scandinavian Tobacco Group. Consumer demand for handmade cigars in the US remained robust in the quarter though with signs at the end of the quarter of a return to the structural declining volume tre

KBC Group: Publication of transparency notification(s) received by KBC Group NV19.5.2022 18:00:00 CEST | Press release

Press release Outside trading hours – Regulated information* Brussels, 19 May 2022, 18h00 Publication of transparency notification(s) received by KBC Group NV (art. 14, 1st section of the Act of 2 May 2007 concerning the disclosure of significant participations) Summary of the notification(s) KBC Group NV has received a transparency notification on 18 May 2022, which states that FMR LLC holds 3.32% of voting rights in KBC Group, based on’ voting securities’ and ‘financial instruments that are treated as equivalent to voting securities’ combined (compared to 3.01% in the previous notification dd. 6 September 2018). That is the sum of 2.72% for voting securities (compared to 3.01% in the previous notification) and 0.60% for financial instruments that are treated as equivalent to voting securities (compared to 0% in the previous notification). Content of the notification(s) The notification(s) contain(s) following information: Reason for the notification(s): acquisition or disposal of vot